Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (SONIMEL01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04021420
Recruitment Status : Not yet recruiting
First Posted : July 16, 2019
Last Update Posted : July 16, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Anti PD-1 monoclonal antibodies (nivolumab and pembrolizumab) alone or in association with antiCTLA4 (Ipilimumab) are established as indisputable treatment of metastatic melanoma, with unprecedented overall survival, and are indicated for first-line treatment including patients with BRAF mutation. Given their high molecular weight, their penetration in the brain sanctuary is uncertain and relies on disruption of the Blood Brain Barrier (BBB) which occurs occasionally.

SonoCloud® is an implantable device delivering low intensity pulsed UltraSound (US). Along with systemic injection of an US resonator, SonoCloud® demonstrated safe and efficient at repetitively opening the BBB. The investigators anticipate that BBB opening could help at increasing brain penetration of monoclonal antibodies and potentially boosting immunity in the brain. This could translate in controlling brain disease with the same magnitude as for extra-cranial disease. This would also open avenues for optimizing the treatment of brain metastases in combination with checkpoint inhibitors in many other cancers.


Condition or disease Intervention/treatment Phase
Melanoma Metastatic Melanoma Device: SONOCLOUD Drug: Nivolumab Injection Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 21 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of Blood Brain Barrier Opening With Implantable Device Sonocloud® Combined With Nivolumab Used Alone or an Association With Ipilimumab in Brain Metastases From Patients With Malignant Melanoma
Estimated Study Start Date : July 5, 2019
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : July 5, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: low intensity pulsed UltraSound
SonoCloud® is an active implantable device (implantation duration until 16 weeks at maximum after inclusion). SonoCloud® delivers low intensity pulsed UltraSound (US). Along with systemic injection of an US resonator, SonoCloud® demonstrated safe and efficient at repetitively opening the BBB.
Device: SONOCLOUD

The SonoCloud System is an active implantable medical. The SonoCloud is indicated to locally and transiently increase the permeability of the blood brain barrier to facilitate the passage of substances into the cerebral parenchyma.

The SonoCloud System consists of :

  1. an implantable ultrasound transducer,
  2. a needle connection device,
  3. an external radiofrequency generator, and
  4. an ultrasound resonator. The SonoCloud® is designed to be fixed to the skull. The device is placed in a burr hole or in place of a bone flap and ultrasound energy is delivered directly to the brain tissue, without traversing the skull bone. The device is activated by connecting the implant to the external generator system using the transdermal needle. Once connected to the external generator, the implant delivers low-intensity pulsed UltraSound (US) for duration of 120-270 seconds. A total of 3 US dose levels will be evaluated (0.78, 0.9 and 1.03 MPa).

Drug: Nivolumab Injection
Nivolumab (flat dose: 240mg, 30 minutes infusion)




Primary Outcome Measures :
  1. Most Successful Dose (MSD) [ Time Frame: Week 6 ]

    Dose with the highest probability of BBB opening efficacy without toxicity directly related to the ultrasound emission.

    Toxicity evaluation:

    Safety will be assessed clinically and using brain Magnetic resonance imaging (MRI). An electroencephalogram will be performed only if clinically needed. Dose-Limiting-Toxicities (DLTs) evaluation will be done during the first 4 weeks of treatment for Nivolumab treatment and 6 weeks for Nivolumab + Ipilimumab treatment. DLTs directly related to the ultrasound emission are defined as occurrence of an adverse effect during the first administration of treatment, such as: :

    • neurological deficit within 2 days after the procedure and persistent at day 15;
    • localized brain edema not preexisting to the procedure;
    • occurrence of cerebral median line deviation not controlled by routine treatment or requiring salvage surgical procedure;
    • partial epilepsy induced or enhanced after the procedure and not control


Secondary Outcome Measures :
  1. Best overall response rate, M3 [ Time Frame: Month 3 ]

    Best clinical objective response (BOR) (defined with the Response assessment in neuro-oncology criteria (RANO) and immunotherapy response assessment for neuro-oncology (iRANO) and the response evaluation criteria in solid tumours (RECIST) version 1.1 and the Immune-Related Response Criteria during the 3 first months

    RANO : Wen, Patrick Y., et al. "Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group." J Clin Oncol 28.11 (2010): 1963-1972.

    iRANO : Okada, Hideho, et al. "Immunotherapy response assessment in neuro-oncology: a report of the RANO working group." The Lancet Oncology 16.15 (2015): e534-e542.


  2. Overall response rate, M3 [ Time Frame: Month 3 ]
    Clinical objective response (defined with the RANO and iRANO and the RECIST version 1.1 and the Immune-Related Response Criteria) during the 3 first months

  3. Best intracranial overall response rate (BICORR), M3 [ Time Frame: Month 3 ]
    Clinical efficacy will be assessed using TEP/TDM Scans (extracranial lesions) and MRI (intracranial metastases) at Month 3

  4. Intracranial overall response rate (ICORR), M3 [ Time Frame: Month 3 ]
    Clinical efficacy will be assessed using TEP/TDM Scans (extracranial lesions) and MRI (intracranial metastases) at Month 3

  5. Best extracranial overall response rate (BECORR), M3 [ Time Frame: Month 3 ]
    Best clinical objective response rate not taking account BICORR

  6. Extracranial overall response rate (BECORR), M3 [ Time Frame: Month 3 ]
    Clinical objective response not taking account ICORR



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically confirmed metastatic melanoma
  • Patients must have recovered from all side effects of their most recent systemic or local treatment for metastatic melanoma (grade ≤ 1).
  • At least one measurable brain metastasis between 5 mm and 35 mm in diameter, not previously treated with surgery and/or radiosurgery and located less than 5 cm from the skull
  • Patients may have received -or not- prior radiosurgery and/or surgery for brain metastases; if they have received prior local treatment, they must have at least 1new RANO and RECIST assessable brain metastases.
  • BRAF status wild type or mutated (and in that case previous treatment with BRAF inhibitor and MEK inhibitor allowed)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1.
  • Age >18 year
  • Hemoglobin ≥10g/dl
  • Platelets ≥ 100000mm3
  • Neutrophils ≥1500/mm3
  • Creatinine Clearance ≥ 50ml/mn
  • AST <3N
  • ALT<3N
  • Total bilirubin <1.5N
  • Alkaline phosphatase <3N
  • INR < 1.5
  • Prothrombin ≥70%
  • TCA <1.2
  • No Hepatocellular insufficiency
  • No unhealed wound on the head
  • No allergy to poly isoprene
  • Signed informed consent
  • Patient with health insurance coverage
  • Life expectancy > 3 months

Exclusion Criteria:

  • Patient previously treated by antiPD1 (except adjuvant antiPD1 therapy)
  • Ocular melanoma
  • Symptomatic or diffuse leptomeningeal involvement.
  • Symptomatic hemorrhagic brain metastases.
  • Symptoms of incoercible intracranial pressure; patients receiving corticosteroids and patients presenting intermittent seizures can be enrolled if they have a stable dose of corticosteroids (≤ 30mg/day corticotherapy) and anti-epileptic treatment since at least 2 weeks before enrolment.
  • Indication for urgent neurosurgery or radiotherapy
  • Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured or stage I untreated Chronic Lymphoid Leukemia.
  • Known human immunodeficiency viruses (HIV) infection and any ongoing infectious disease or significant background.
  • Concurrent administration of any anticancer therapies other than those administered in this study.
  • Treatment with any cytotoxic and/or investigational drug, antiCTLA4 or targeted therapy ≤ 4 weeks or <5 half lives for targeted therapies or chemotherapy, prior to day 1 of study.
  • Prior whole brain radiotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04021420


Contacts
Layout table for location contacts
Contact: LEBBE Celeste, MD, PhD 142494679 ext +33 celeste.lebbe@aphp.fr
Contact: Matthieu RESCHE-RIGON, MD PhD 142499742 ext +33 matthieu.resche-rigon@univ-paris-diderot.fr

Locations
Layout table for location information
France
Saint-Louis Hospital Not yet recruiting
Paris, France, 75010
Contact: Celeste LEBBE, MD-PHD    142494679 ext +33    celeste.lebbe@aphp.fr   
Contact: El-Mountacer el-abbassi    142499742 ext +33    el-abbassi.el-mountacer@univ-paris-diderot.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT04021420     History of Changes
Other Study ID Numbers: P160950J
First Posted: July 16, 2019    Key Record Dates
Last Update Posted: July 16, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents